Standard of care treatment for primary bone cancer patients involves surgery to remove the entire cancer and a significant region of tissue from around the tumour. After surgery, patients need additional treatment to repair the area where the bone was removed, ensure it is functional and to prevent the cancer coming back (recurrence).
Depending on the size of the area of bone that is removed, different surgeries are necessary to repair the lost bone. Small bone areas, often the case in chordoma, can be repaired using man-made bone materials, known as ‘synthetic biomaterials’ or with bone harvested from the patient. For larger tumours, as is normally the case in osteosarcoma, orthopaedic implants are required.
Regardless of the method chosen to replace the bone that is removed, neither help prevent recurrence.
Chemotherapy is often used in osteosarcoma after surgery, to destroy any cancer cells which may remain in the area, but of course, chemotherapeutics cause severe toxicity and are ineffective in chordoma.
What were the aims of this research project?
Gallium-nitrate is an inorganic material that is effective in destroying cancer cells. Unlike chemotherapy, it does not deplete white blood cells and platelets and it has been shown to enhance the re-generation of bone. The downside of this treatment is that it must be given by a continuous intravenous infusion for 5-7 days, which is highly restrictive for patients.
Professor Richard Martin, at the University of Aston, in collaboration with Professor Lee Jeys at the Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, aimed to develop gallium containing synthetic biomaterials, a smart synthetic bone grafts with bone-repairing and cancer-killing properties to be used in the treatment of patients with osteosarcoma. Such material would drastically improve the outcomes of the current therapy by reducing the likelihood of implant failure and cancer recurrence. Four different bone cancer cells lines and one control cell line of normal human osteoblasts were treated with different concentrations of gallium to identify the “therapeutic window”, i.e., the range of doses that are capable of killing bone cancer cells without affecting the healthy cells.

Results of the study:
Cell lines were treated with a series of gallium doped bioactive glasses for up to 7 days. Complete kill of two of the four cancer cell lines was achieved and strong therapeutic window was identified for another of the bone cancer cell lines (experiments are still on-going to hopefully demonstrate that we achieve complete kill for the third cell line). One of the cancer cell lines was more difficult to kill and we are still trying to identify if there is a therapeutic window available. In summary we believe the current materials would be highly effective against 3 of the 4 bone cancer cell lines tested.
The team now plan to build upon this knowledge and produce scaffolds to be used in the reconstructive surgery of sarcoma patients.
It is expected that these materials will significantly reduce healing time and reduce local cancer reoccurrence. These materials have the potential to reduce the need for additional chemotherapy and improve outcomes for patients.
Sponsor Our Research Into Osteosarcoma Sponsor Our Research Into Chordoma